

BIOGRAPHICAL SKETCH
Complete for each professional associated with the project

Name: <i>[Last, First, Middle Initial(s), Degree(s)]</i> Buttari Fabio, MD, PhD	Position/Title: Consultant neurologist
--	---

Education

Institution and Location	Degree	Year Conferred	Field of Study
University of Rome "La Sapienza"	MD	2005	Research thesis on the following topic "Familial and sporadic Alzheimer's disease: a clinical comparison"
University of Rome "Tor Vergata"	Neurologist	2013	Research thesis on the following topic "Opposite roles of NMDA receptors in relapsing and primary progressive Multiple Sclerosis"
University of Rome "Tor Vergata"	PhD	2017	Research thesis on the following topic "miR-142-3p is a key regulator of IL-1 β -dependent synaptopathy in neuroinflammation"

Research and Professional Experience

[List in chronological order, previous employment, experience and honors]

2002-2007 Resident in Neurology at University of Rome “La Sapienza” - Umberto I General Hospital in Rome

2008–to date Attending Multiple Sclerosis Centre and Clinical Research Activities of University of Rome “Tor Vergata” - Tor Vergata General Hospital in Rome

2008-to date Co-investigator in clinical trials (II, III, IV phase) according to GCP at Multiple Sclerosis Centre and Clinical Research Activities of University of Rome “Tor Vergata” - Tor Vergata General Hospital in Rome

2013 Research Fellow at University of Rome “Tor Vergata” - Tor Vergata General Hospital in Rome

2015 and 2017 Consultant neurologist at I.R.C.C.S. Istituto Neurologico Mediterraneo Neuromed in Pozzilli (IS)

Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

TRPV1 polymorphisms and risk of interferon β -induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. **Buttari F**, Zagaglia S, Marciano L, Albanese M, Landi D, Nicoletti CG, Mercuri NB, Silvestrini M, Provinciali L, Marfia GA, Mori F, Centonze D. *J Neuroimmunol*. 2017 Apr 15;305:172-174.

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, **Buttari F**, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. *Neurology*. 2017 Feb 22.

miR-142-3p Is a Key Regulator of IL-1 β -Dependent Synaptopathy in Neuroinflammation. Mandolesi G, De Vito F, Musella A, Gentile A, Bullitta S, Fresegna D, Sepman H, Di Sanza C, Haji N, Mori F, **Buttari F**, Perlas E, Ciotti MT, Hornstein E, Bozzoni I, Presutti C, Centonze D. *J Neurosci*. 2017 Jan 18;37(3):546-561.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. Prosperini L, Saccà F, Cordioli C, Cortese A, **Buttari F**, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C. *J Neurol*. 2017 Feb;264(2):284-294.

Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. Bargagli AM, Colais P, Agabiti N, Mayer F, **Buttari F**, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M. *J Neurol*. 2016 Apr;263(4):751-9.

Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. Albanese M, Zagaglia S, Landi D, Boffa L, Nicoletti CG, Marciani MG, Mandolesi G, Marfia GA, **Buttari F**, Mori F, Centonze D. *J Neuroinflammation*. 2016 Feb 10;13:36.

Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. Ghezzi A, Mutta E, Bianchi F, Bonavita S, **Buttari F**, Caramma A, Cavarretta R, Centonze D, Coghe GC, Coniglio G, Del Carro U, Ferrò MT, Marrosu MG, Patti F, Rovaris M, Sparaco M, Simone I, Tortorella C, Bergamaschi R. *Neurol Sci*. 2016 Mar;37(3):437-42.

Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis. Gentile A, De Vito F, Fresegna D, Musella A, **Buttari F**, Bullitta S, Mandolesi G, Centonze D. *Front Cell Neurosci*. 2015 Jun 25;9:243.

Epstein-Barr virus genetic variants are associated with multiple sclerosis. Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D'Erchia AM, Buscarinu MC, Agliardi C, Annibaldi V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, **Buttari F**, Battistini L, Centonze D, Guerini FR, D'Alfonso S, Pesole G, Salvetti M, Ristori G. *Neurology*. 2015 Mar 31;84(13):1362-8.

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Prosperini L, Annovazzi P, Capobianco M, Capra R, **Buttari F**, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A. *Mult Scler*. 2015 Nov;21(13):1713-22.

CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis. Mori F, Ljoka C, Nicoletti CG, Kusayanagi H, **Buttari F**, Giordani L, Rossi S, Foti C, Centonze D. *Neurol Neuroimmunol Neuroinflamm*. 2014 Dec 11;1(4):e48.

Interleukin-1 β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Rossi S, Motta C, Studer V, Macchiarulo G, Volpe E, Barbieri F, Ruocco G, **Buttari F**, Finardi A, Mancino R, Weiss S, Battistini L, Martino G, Furlan R, Drulovic J, Centonze D. *Mol Neurodegener*. 2014 Dec 12;9:56.

Firma

